Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. F. Fitzgerald, D. Spicer, H. Lisle, N. Bowyer, R. G. Sturton, D. Minshall, B. Meshi, D. Ionescu, M. T. Shrad, J. C. Hogg (Stoke Poges, United Kingdom; Vancouver, Canada). Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig. Eur Respir J 2001; 16: Suppl. 31, 339

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 The selective PDE4-inhibitor AWD 12-281 inhibits LPS-induced neutrophilia in domestic pig lung, an animal model of COPD: comparison with steroids Source: Eur Respir J 2001; 18: Suppl. 33, 160s Year: 2001 A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004 The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011 Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in guinea pigs Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 AWD 12-281, a new PDE4-inhibitor, suppresses allergen-induced [DCquote]early phase“ bronchoconstriction in sensitized guinea pigs Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Discovery of competitive thromboxane receptor (TP) antagonism by diclofenac in guinea pig airway and vascular tissues Source: Annual Congress 2007 - Recent advances in airway smooth muscle biology Year: 2007 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 Effects of pendrin inhibitor (PDI_C01) in vitro, and in vivo models of lipopolysaccharide-induced airway inflammation. Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019 A novel TRPA1 antagonist inhibits ovalbumin-induced bronchoconstriction in guinea pig models Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury Source: Eur Respir J 2003; 22: 20-27 Year: 2003 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Treatment with proteinase inhibitor, BbCI, modulates inflammatory response, mechanic alterations, and remodeling on elastase-induced emphysema in mice Source: Annual Congress 2012 - The many roads to lung injury Year: 2012